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7545-Azacytidine as Salvage Treatment in Relapsed
Myeloid Tumors after Allogeneic Bone
Marrow Transplantation
Javier Bola~nos-Meade, B. Douglas Smith, Steven D. Gore, Michael A. McDevitt,
Leo Luznik, Ephraim J. Fuchs, Richard J. JonesRelapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies
for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually
toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received
5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete
remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient
has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with
5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days
(127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic
bone marrow transplant, and prospective studies are warranted.
Biol Blood Marrow Transplant 17: 754-758 (2011)  2011 American Society for Blood and Marrow TransplantationKEY WORDS: Acute myeloid leukemia, Donor lymphocyte infusion, 5-Azacytidine, Myelodysplastic
syndrome, Graft-versus-host diseaseINTRODUCTION
Patients who relapse after allogeneic blood and
marrow transplant (BMT) for acute myeloid leukemia
(AML) or myelodysplastic syndromes (MDS) have
very poor prognoses [1]. Survival is generally short
with traditional salvage therapies such as further che-
motherapy or donor lymphocyte infusions (DLI)
[1,2]. Thus, there is a great need for new therapeutic
approaches in this setting.
The DNA methyltransferase inhibitor 5-azacytidine
is effective treatment forMDS, with 20% to 30% com-
plete and partial responses as well as improved survival
compared to best supportive care [3,4]. Preliminary
data suggest that 5-azacytidine has similar activity in
some subsets of AML [5,6]. Hypomethylating agents‘‘George W. Santos’’ Bone Marrow Transplant Service,
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6/j.bbmt.2010.10.008may play a role in effectively stabilizing MDS prior to
allogeneic BMT [7,8]. Moreover, it appears that the
drug may have immunolomodulatory properties that
could potentially enhance the graft-versus-leukemia
effect associated with allogeneic BMT [9,10]. Recent
reports also suggest that 5-azacytidine may have
activity in patients with relapse after allogeneic BMT
[11-13]. On the basis of this information, 5-azacytidine
has been used at our institution to treat patients with
progressive AML or MDS after BMT.MATERIALS AND METHODS
We retrospectively identified all patients with
myeloid malignancies who were treated with 5-azacy-
tidine for relapse after allogeneic BMT between 2007
and 2009 at Johns Hopkins Hospital. There was a pro-
grammatic decision to consider treatment of relapses
of myeloid malignancies after allogeneic BMT with
5-azacytidine in 2007, but the final decision on treat-
ment was determined by the primary physician caring
for the patient (whether to enroll on a clinical trial, give
5-azacytidine, or refer to hospice care, for instance).
Evidence of recurrent disease was defined as decreas-
ing or loss of donor chimerism usually with morpho-
logic or cytogenetic persistence of the primary
disease. Patients received supportive care including
blood product support as needed. Patients were fol-
lowed for morphological response, chimerism, and
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Biol Blood Marrow Transplant 17:754-758, 2011 7555-Azacytidine after Failed Allogeneic BMTsurvival. This analysis was approved as being exempt
from human subjects research by the Johns Hopkins
Hospital institutional review board and written and
electronic medical records were retrospectively ana-
lyzed. The survival analyses were completed as of
May 1, 2010.
Chimerism was measured as follows. Unsorted and
CD31 cells are separated from peripheral blood, or
unsorted bone marrow cells, using the RoboSep auto-
mated instrument (StemCell Technologies, Vancouver,
Canada). This assay consists of PCR amplification of
(15) microsatellite markers and the amelogenin locus
using AmpFlSTR Identifiler PCR Amplification Kit
(Applied Biosystems, Foster City, CA, USA). The
resulting PCR products are analyzed by capillary elec-
trophoresis and the peak heights of the informative
alleles are compared to calculate a percentage engraft-
ment. In general, engraftment is calculated using 2 dif-
ferent microsatellite loci from a single PCR reaction.
The true limit of detection for an individual reaction is
both locus and PCR dependent. The formal limit of
detection is 5% [14,15].
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].RESULTS
Patients
Between 2007 and 2009, 154 allogeneic transplants
for 149 patients with myeloid malignancices were per-
formed at Johns Hopkins Hospital. A total of 37 re-
lapses were identified during that time frame, and 10
of these patients were identified as having received 5-
azacytidine for disease progression after BMT (Table 1).
One was previously reported [13]. Their median age
was 55 years (range: 25-67).Threeweremales, and 7 fe-
males. None of the patients were known to be positive
for a FLT3 ITD, patients 1, 7, 9, and 10 were FLT3
ITDnegative, and the rest were not tested.None of the
patients had active graft-versus-host disease (GVHD)
or were on immunosuppression at the time of starting
therapy. None of the patients had blasts in peripheral
blood at the time of starting therapy.
Therapy
Patients received 5-azacytidine following different
schedules as per the treating physician (Table 2), but
most patients received 75 mg/m2/day for either 5 or
7 days. One patient received 5-azacytidine in combina-
tion with the histone deacetylase inhibitor entinostat
as previously reported [16]. The median number of
cycles administered was 6 (range: 2-27).
Outcome
Therapy was well tolerated with no unexpected or
severe toxicities. One of the patients (a nonresponder)
was admitted to the hospital for neutropenic fevers
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756 Biol Blood Marrow Transplant 17:754-758, 2011J. Bola~nos-Meade et al.and fungal infection. Of the 10 patients treated with
5-azacytidine, 6 achieved complete remissions and
4 did not respond (1 stable disease, and 3 disease
progressions) (Table 2). Achievement of complete
remission was associated with complete loss of host
chimerism in 4 patients and near loss in the 2 others.
Three patients received DLI after treatment (2 after
achieving a complete remission); 2 remain in complete
remission, 1 of whom developed extensive chronic
GVHD (cGVHD), and 1 died of disease progression.
The median survival (from the time of relapse before
starting 5-azacytidine) for the group was 422.5 (127-
1411) days. Of the 6 patients who achieved a complete
remission, 5 remain disease-free at a median follow-up
of 624 (162-771) days. Of the 27 other relapses in the
myeloid malignancy patients, only 5 remain alive.DISCUSSION
The management of disease relapse after allogeneic
BMT is challenging. DLI has traditionally been stan-
dard practice. Porter et al. [17] identified recipients of
unrelated DLI for the treatment of relapsed disease
from theNMDPdatabase.UnrelatedDLIwas adminis-
tered for relapsed AML to 23 patients. Forty-two
percent (8 out of 19) of assessable patients with AML
achieved a complete response. The estimated probabil-
ity of DFS at 1 year after a complete response was
23%. Acute and cGVHDwere commonly seen in these
patients. Huff et al. [2] retrospectively analyzed 83 con-
secutive recipients of DLI after BMT. In relapsed acute
myeloid leukemia (13 patients),DLI led todurable com-
plete responses in 31% of patients. Grade II or higher
acute GVHD (aGVHD) or cGVHD occurred in 43%
patients and contributed to death in 16%. Schmid
et al. [18] analyzed the outcome of 399 patients in first
hematologic relapse included in the European Group
for Blood and Marrow Transplantation. Of these, 171
received DLI and 228 did not. At 2 years, 21% of those
receivingDLIwere alive versus 9%of thosewhodidnot.
The low likelihood of achieving prolonged survival
without comorbid GVHD after DLI provides the
rationale for novel investigations and approaches.There
are emerging data suggesting activity for 5-azacytidine
for relapse after allogeneic BMT. Jabbour et al. [11]
reported on 5-azacytidine (doses ranging from 16-40
mg/m2) as salvage therapy and on 8 patients as mainte-
nance after allogeneic. The treatment was well tolerated
with no grade 3-4 toxicities, and 5 of 9 patients with
recurrent disease responded without exacerbations of
GVHD. After a median follow up of 16 months, 14
patients are alive including 7 in CR. L€ubbert et al. [12]
administered 5-azacytidine for 3 days (100 mg/day)
followed by DLI on day 10 every 21 days to patients
relapsed after allogeneic BMT. The median survival
for the 26 patients (who received a total of 60 courses
Biol Blood Marrow Transplant 17:754-758, 2011 7575-Azacytidine after Failed Allogeneic BMTof treatment) from the start of 5-azacytidine was 136
days. Toxicities related to the 5-azacytidine are hard to
evaluate because of the addition for DLI.
In our cohort, treatment with 5-azacytidine was well
tolerated, with sustained responses in many of the pa-
tients without exacerbations of GVHD. The potential
immunologic antitumor effects of 5-azacytidine are still
unclear. Hypomethylating agents including 5-azacyti-
dine have been reported to reverse the loss of expression
of tumor-specific, tumor-associated, or histocompatibil-
ity antigens on tumor cells, making themmore suscepti-
ble to immune attack [19-23]. Hypomethylating agents
may also enhance presentation of tumor antigens
[9,10,24], which may be expected to generate a graft-
versus-tumor reaction. The drug has also been
reported to inhibit T cell proliferation and activation,
decreasing the production of proinflammatory
cytokines such as tumor necrosis factor-alpha (TNF-a)
and interferon-gamma (INF-g), which may prevent
GVHD and possibly graft-versus-tumor effects as well
[25]. It also induces FOXP3 expression inCD41CD252
T cells both in vitro and in vivo [26].
Conversely, 5-azacytidine may induce cytotoxic T
lymphocytes with activity against AML [27]. Regard-
less of the exact mechanism of action, there are now
several small studies that support the development of
larger, prospective clinical trials to better characterize
the safety and efficacy of 5-azacytidine after allogeneic
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